Hr Breast Cancer clinical trials

Explore recruiting hr breast cancer clinical trials.

Recruiting hr breast cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hr Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer

France, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Randomized Phase II Study to Evaluate the Incidence of Discontinuations due to Diarrhoea at 3 Cycles in patients with Early-stage HER2-positive (HER2+), Hormone Receptor-positive (HR+) Breast Cancer treated with Neratinib plus Loperamide prophylaxis versus Neratinib with Initial Dose Escalation plus PRN Loperamide prophylaxis versus Neratinib plus Loperamide plus Colesevelam prophylaxis. “DIANER Study”

Spain, Croatia, Italy, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Study to Investigate the Efficacy and Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms (Hot Flashes) in Women with Stage 0 to 3 Hormone Receptor-positive Breast Cancer Who Are Receiving Adjuvant Endocrine Therapy

Hungary, Denmark, Italy, Czechia, Germany, France +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT PLUS RIBOCICLIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+) BREAST CANCER​ (THE CADILLAC STUDY)

Spain, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCER PATIENTS

Germany

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors

France, Italy, Belgium, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Hr Breast Cancer trials by city

Hr Breast Cancer in Toronto Hr Breast Cancer in Vancouver Hr Breast Cancer in Montreal Hr Breast Cancer in Calgary Hr Breast Cancer in Edmonton Hr Breast Cancer in Ottawa Hr Breast Cancer in Winnipeg Hr Breast Cancer in Quebec City Hr Breast Cancer in Hamilton Hr Breast Cancer in Kitchener Hr Breast Cancer in London Hr Breast Cancer in Halifax Hr Breast Cancer in New York Hr Breast Cancer in Los Angeles Hr Breast Cancer in Chicago Hr Breast Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease